Search

Your search keyword '"Liberatore, Giuseppe"' showing total 136 results

Search Constraints

Start Over You searched for: Author "Liberatore, Giuseppe" Remove constraint Author: "Liberatore, Giuseppe"
136 results on '"Liberatore, Giuseppe"'

Search Results

1. Correction to: Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian database

2. Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

4. Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian database

5. Prolonged distal motor latency of median nerve does not improve diagnostic accuracy for CIDP

6. Prospective open- label trial with rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy not responding to conventional immune therapies.

7. The neurophysiological lesson from the Italian CIDP database

8. Cytokines and chemokines in patients with chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: A systematic review

9. Correction to: Frequency and clinical correlates of anti-nerve antibodies in a large population of CIDP patients included in the Italian database

10. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context

11. Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy

12. Impact of 2021 European Academy of Neurology/Peripheral Nerve Society diagnostic criteria on diagnosis and therapy of chronic inflammatory demyelinating polyradiculoneuropathy variants.

14. Unclassified clinical presentations of chronic inflammatory demyelinating polyradiculoneuropathy

15. The circular RNA landscape in multiple sclerosis: Disease-specific associated variants and exon methylation shape circular RNA expression profile

16. Comparison of the diagnostic accuracy of the 2021 EAN/PNS and 2010 EFNS/PNS diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy

17. Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies

18. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy

19. A diagnostic score for anti‐myelin‐associated‐glycoprotein neuropathy or chronic inflammatory demyelinating polyradiculoneuropathy in patients with anti‐myelin‐associated‐glycoprotein antibody.

20. A diagnostic score for anti‐myelin‐associated‐glycoprotein neuropathy or chronic inflammatory demyelinating polyradiculoneuropathy in patients with anti‐myelin‐associated‐glycoprotein antibody

21. A diagnostic score for anti-MAG neuropathy or CIDP in patients with anti-MAG antibody

22. sj-docx-1-msj-10.1177_13524585221102918 – Supplemental material for Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies

23. Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy

24. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies

25. A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity

26. Genetic variants are major determinants of CSF antibody levels in multiple sclerosis

27. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

28. Chronic inflammatory demyelinating polyradiculoneuropathy: Can we make a diagnosis in patients not fulfilling electrodiagnostic criteria?

29. Familial clustering in Italian progressive-onset and bout-onset multiple sclerosis

31. Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy

32. Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy

35. Risk factors for CIDP: antecedent events, lifestyle and dietary habits. Data from the Italian CIDP database

36. Atypical CIDP: Diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database

37. Relevance of diagnostic investigations in chronic inflammatory demyelinating poliradiculoneuropathy: Data from the Italian CIDP database.

38. Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database

39. Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response

40. Genetic variants are major determinants of CSF antibody levels in multiple sclerosis.

41. Familial clustering in Italian progressive-onset and bout-onset multiple sclerosis

42. A pharmacogenetic study implicatesSLC9a9in multiple sclerosis disease activity

43. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis

44. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis

45. Validation of 1-year predictive score of long-term response to interferon-β in everyday clinical practice multiple sclerosis patients.

46. A diagnostic score for anti-myelin-associated-glycoprotein neuropathy or chronic inflammatory demyelinating polyradiculoneuropathy in patients with anti-myelin-associated-glycoprotein antibody

47. Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies

48. Comparison of the diagnostic accuracy of the 2021 EAN/PNS and 2010 EFNS/PNS diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy

49. Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy

50. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

Catalog

Books, media, physical & digital resources